Antares Pharma (Nasdaq: ATRS) reported earnings on Aug. 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Antares Pharma missed estimates on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share improved.
Margins dropped across the board.
Revenue details
Antares Pharma reported revenue of $4.5 million. The three analysts polled by S&P Capital IQ foresaw a top line of $4.6 million on the same basis. GAAP reported sales were 28% higher than the prior-year quarter's $3.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at -$0.03. The one earnings estimate compiled by S&P Capital IQ predicted -$0.03 per share. GAAP EPS were -$0.03 for Q2 compared to -$0.02 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 44.1%, 1,660 basis points worse than the prior-year quarter. Operating margin was -61.7%, 1,660 basis points worse than the prior-year quarter. Net margin was -62.0%, 1,810 basis points worse than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $6.4 million. On the bottom line, the average EPS estimate is -$0.01.
Next year's average estimate for revenue is $25.3 million. The average EPS estimate is -$0.04.
Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 161 members out of 176 rating the stock outperform, and 15 members rating it underperform. Among 21 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 16 give Antares Pharma a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is buy, with an average price target of $4.50.
- Add Antares Pharma to My Watchlist.
